» Articles » PMID: 14669949

The Putative Role of Fibroblasts in the Pathogenesis of Graves' Disease: Evidence for the Involvement of the Insulin-like Growth Factor-1 Receptor in Fibroblast Activation

Overview
Journal Autoimmunity
Date 2003 Dec 13
PMID 14669949
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Graves' disease when fully expressed affects the thyroid gland and connective tissues of the orbit and pretibium. While the glandular disease is relatively well-characterized, the pathogenesis of the orbital and dermal components remains enigmatic. In the following article, we review some of the evidence suggesting that fibroblast activation in Graves' disease might play an integral role in the tissue remodeling associated with ophthalmopathy. The thyrotropin receptor (TSHR) is expressed at low levels in several connective tissue depots and by their derivative fibroblasts, including those from the orbit. Little direct evidence currently links extra-thyroidal TSHR expression with Graves' disease. Very recent observations now implicate the insulin-like growth factor-1 receptor (IGF-1R) as a fibroblast activating antigen. When immunoglobulins from patients with the disease, with or without clinical ophthalmopathy, bind IGF-1R on the surface of fibroblasts, the receptor becomes activated and upregulates the expression of two T lymphocyte chemoattractants, IL-16 and RANTES. Thus, IGF-1R may represent a second self-antigen with a pathogenic role in extra-thyroidal Graves' disease.

Citing Articles

Teprotumumab for Treatment of Pretibial Myxedema.

Reyes M, Cabrera J, Singh J, Turnbull D JCEM Case Rep. 2023; 1(1):luac037.

PMID: 37908268 PMC: 10578414. DOI: 10.1210/jcemcr/luac037.


NIH/3T3 Fibroblasts Selectively Activate T Cells Specific for Posttranslationally Modified Collagen Type II.

Dzhambazov B, Batsalova T, Merky P, Lange F, Holmdahl R Int J Mol Sci. 2023; 24(13).

PMID: 37445989 PMC: 10341784. DOI: 10.3390/ijms241310811.


Thyroid dermopathy responds to teprotumumab therapy.

Crespo-Trevino R, Schiffman J, Ugradar S, Cockerham K, Douglas R, de Leon-Garza D Endocrinol Diabetes Metab Case Rep. 2022; 2022.

PMID: 35319490 PMC: 9002184. DOI: 10.1530/EDM-21-0201.


Diosgenin From Dioscorea Nipponica Rhizoma Against Graves' Disease-On Network Pharmacology and Experimental Evaluation.

Xin J, Cheng W, Yu Y, Chen J, Zhang X, Shao S Front Pharmacol. 2022; 12:806829.

PMID: 35140607 PMC: 8819592. DOI: 10.3389/fphar.2021.806829.


Thyroid Eye Disease: Navigating the New Treatment Landscape.

Dosiou C, Kossler A J Endocr Soc. 2021; 5(5):bvab034.

PMID: 33948524 PMC: 8078830. DOI: 10.1210/jendso/bvab034.